Intelligent Automation Company Bioyond Nets More than 2 Bn in Series A

Healthcare Author: Yunfeng Zhang Apr 07, 2023 05:28 PM (GMT+8)

Based on the three core technology platforms, the company has provided services to more than 100 well-known companies in the life science field

medical care

Bioyond Technology(Chinese: 奔曜科技), an intelligent automation company in life sciences, announced that it has completed two consecutive rounds of financing of about 200 million RMB in Series A and Series A+. The A round was led by a well-known industrial fund, and the A+ round was co-led by Boyuan Capital and Lilly Asia Fund (LAV), followed by CICC Qide Fund, a subsidiary of CICC Capital, with continued follow-on investment from old shareholders Qiming Venture Capital, Sequoia China Seed Fund, and Zhangke Harun Fund.

 Headquartered in Shanghai Zhangjiang Science City, Bioyond Technology is focused on transforming intelligent automation in life sciences, using robotics, automation and artificial intelligence technologies to provide automation products and solutions for a wide range of fields including small molecule drugs, biologics, cellular gene therapy, Chinese medicine, synthetic biology, histology research, clinical diagnostics and materials science.

 It is reported that Sequoia China Seed Fund participated in the company's incubation at the beginning of Bioyond Technology's creation, and provided angel round financing in early 2021. In the same year, the company received a Pre-A round of financing led by Qiming Venture Capital, followed by Sequoia China Seed Fund and Zhangke Harun Fund.

 Up to now, in less than 2 years of its establishment, Bioyond Technology has completed 4 rounds of financing with a total amount of about 300 million RMB. The funds raised will be used for product development and production, platform construction, and market expansion to accelerate the provision of easier-to-use and more efficient automation products and solutions for pharmaceuticals, clinical diagnostics, scientific research, and material chemicals.

 At present, Bioyond Technology has three core technology platforms: robotics, automation, data and cloud. To meet the needs of life science industry users, the company has created a flexible combination and rapid deployment automation system based on a full stack of self-developed high-performance flexible robots, rich instrument modules and easy-to-use intelligent software; at the same time, with advanced artificial intelligence and computing engine, the system can realize massive data processing, providing reliable scientific analysis and decision basis for R&D and production personnel.

 Based on the three core technology platforms, the company has provided services to more than 100 well-known companies in the life science field, and its products and solutions are widely used in the fields of small molecule drugs, biological drugs, cellular gene therapy, Chinese medicine, synthetic biology, histology research, clinical diagnosis and material science.

 As for the team, BIOYOND has more than 100 employees, with 70% of R&D staff, spanning disciplines such as robotics, life sciences, digital intelligence, and automation. The founding team has worked as executives in Fortune 500 companies in robotics and life sciences, with deep scientific research background and rich experience in product development.

 After graduating in 2004, he joined ABB Robotics, one of the "Four Families" of international robots, and served as President of ABB Robotics China R&D Center and President of ABB Robotics China Consumer and Service Robotics Business Unit. From automotive and parts, to 3C electronics, to new energy and logistics, Tang Yang is well versed in the development trend of robotics industry. The reason why he turned his attention to life science, he said that the field is undergoing a profound technological change, automation technology will be one of the core drivers to lead and accelerate this change.

 It is reported that automation can play a key role in optimizing the experimental R&D process, improving the standardization of test data, and reducing costs and increasing efficiency in production. Compared to traditional manual operations, which are time-consuming and laborious and may be problematic in terms of repeatability, data traceability, and safety, laboratory automation products can effectively optimize the process, significantly improve efficiency and accuracy, and reduce laboratory and sample contamination, in addition to freeing scientists' hands. With the further rise in labor costs in the post-epidemic era, it has also prompted companies to favor automation solutions that are efficient, stable and more cost-effective in the long term. In addition, with the widespread use of AI in the biopharmaceutical industry, the importance of big data cannot be overstated, and automation will be a powerful tool for generating large amounts of structured, high-dimensional data.